F8257

Flunarizine dihydrochloride

≥98% (TLC)

• Sinónimos: 1-[Bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)piperazine dihydrochloride
• Fórmula empírica (notación de Hill): C₂₆H₂₆F₂N₂ · 2HCl
• Número de CAS: 30484-77-6
• Peso molecular: 477.42
• Beilstein/REAXYS Number: 4284243
• EC Number: 250-216-6
• MDL number: MFCD00058198
• UNSPSC Code: 12352200
• PubChem Substance ID: 24277835
• NACRES: NA.77

Propiedades

• Quality Level: 200
• assay: ≥98% (TLC)
• originator: Johnson & Johnson
• storage temp.: 2-8°C
• SMILES string: Cl[H].Cl[H].Fc1ccc(cc1)C(N2CCN(CC2)C\C=C\c3ccccc3)c4ccc(F)cc4
• InChI: 1S/C26H26F2N2.2ClH/c27-24-12-8-22(9-13-24)26(23-10-14-25(28)15-11-23)30-19-17-29(18-20-30)16-4-7-21-5-2-1-3-6-21;;/h1-15,26H,16-20H2;2*1H/b7-4+;;
• InChI key: RXKMOPXNWTYEHI-RDRKJGRWSA-N

Descripción

General description

Flunarizine has antihistamine, anticonvulsant and vestibular depressive properties. It protects endothelial cells from calcium overload-induced damage. Flunarizine is used to treat epilepsy, migraine prophylaxis, cerebral blood flow disturbances, peripheral vascular disease and vertigo.

Application

Flunarizine dihydrochloride has been used to study the effect of flunarizine on epileptiform activity. It is also used to study its effect on high-potassium induced increase of intracellular free calcium.

Biochem/physiol Actions

Blocks T-type Ca²⁺/Na⁺ channels.

Blocks T-type Ca²⁺/Na⁺ channels; inhibits K⁺-induced catecholamine release from chromaffin cells

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Gloves